Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MC4R | P32245 | 2/20 | 0.42 |
| ▸ | MC1R | Q01726 | 2/20 | 0.42 |
| ▸ | MC3R | P41968 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6699343 | 0.88 | EPHX2 (0.47) | KDM4EHSD17B10KMT2AMEN1LMNA | |
| SCHEMBL6989152 | 0.77 | FAAH (0.54) | KDM4EHSD17B10KMT2AMEN1LMNA | |
| SCHEMBL6698803 | 0.76 | FAAH (0.47) | KMT2AMEN1P2RX7 | |
| SCHEMBL14703433 | 0.76 | MEN1 (0.43) | KMT2AMEN1P2RX7TSHR | |
| SCHEMBL6990296 | 0.76 | FAAH (0.55) | KDM4EHSD17B10KMT2AMEN1LMNA | |
| SCHEMBL6698763 | 0.76 | MEN1 (0.61) | KMT2AMEN1 | |
| SCHEMBL13873878 | 0.75 | EPHX2 (0.72) | KDM4EHSD17B10KMT2AMEN1P2RX7 | |
| SCHEMBL5737566 | 0.73 | P2RX7 (0.55) | KMT2AMEN1P2RX7ALDH1A1MC4R | |
| SCHEMBL6694717 | 0.73 | KDM4E (0.60) | KDM4EHSD17B10KMT2AMEN1LMNA | |
| SCHEMBL6695899 | 0.73 | KMT2A (0.61) | KDM4EHSD17B10KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HONG YUFENG (US) | 2004-03-04 | — | — | US | disclosed |
| EP-1332127-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | Warner-Lambert Company LLC (US) | 2003-08-06 | — | — | EP | disclosed |
| WO-2002036554-A2 | AMIDINO-UREA SEROTONIN RECEPTOR LIGANDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND METHODS FOR THEIR SNYTHESIS | WARNER-LAMBERT COMPANY LLC (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044037-A1 | Amidino-urea serotonin receptor ligands and compositions, their pharmaceutical uses, and methods for their snythesis | HTR7, HTR1A, HTR2C | KDM4E 3900/4885HSD17B10 4099/4885KMT2A 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.